DUBLIN, May 12, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "A-Share Listed Biological Products Companies - Profiles and Financial Data" report to their offering.
In China, biological products include: bacterial vaccines (containing toxoid), viral vaccines, antitoxin and antiserum, blood products, cytokine, growth factors, enzyme, in vivo and in vitro diagnostic products, and other biological active preparations.
According to this report, fast economic growth and residents' increasing income have pushed up people's medical expenses. China's biological products market outperforms the global average. In China, the market size exceeded CNY 130 billion in 2016, but its share in the pharmaceutical market was less than 10%, far below that in developed countries.
In the Thirteenth Five-Year Plan (2016-2020), biotechnological pharmaceuticals, new vaccines, new cell therapy preparations and other innovative pharmaceuticals were listed among the priorities of the bio-medicine industry. It is expected that in the next few years, biotechnological advances and favorable policies will facilitate fast growth of the biological product industry.
The report is composed of two parts: the first part is enterprise profiles and the second part is the operation status of these enterprises in the recent decade.
- Ginwa Enterprise (Group) Inc.
- Beijing Tiantan Biological Products
- Shanghai Fosun Pharmaceutical
- Bluestar Adisseo Company
- Shanghai Jiaoda Onlly
- Zhongyuan Union Cell & Gene Engineering
- Zhejiang Qianjiang Biochemical
- Tonghua Dongbao Pharmaceutical
- Autobio Diagnostics
- Wuhan Thalys Medical Technology
- Shenzhen Cau Technology
- Shenzhen Neptunus Bioengineering
- Zhenxing Biopharmaceutical & Chemical Inc.
- Jiangsu Sihuan Bioengineering
- Changchun High-Tech Industry
- Hualan Biological Engineering
- Shanghai Kehua Bio-engineering
- DAAN Gene
- Beijing SL Pharmaceutical
- Shanghai RAAS Blood Products
- Shandong Sinobioway Biomedicine
- Changsheng Bio-technology
- Anhui Anke Biotechnology (Group)
- Chongqing Chifei Biological Products
- Walvax Biotechnology
- Staidson (Beijing) Biopharmaceuticals
- Baotou Dongbao Bio-Tech
- (10+ Others)
Key Topics Covered:
1. Financial Indexes
2. Summary of Income Statement
3. Summary of Balance Sheet
4. Summary of Cash Flow Statement
For more information about this report visit http://www.researchandmarkets.com/research/n924xc/ashare_listed
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/a-share-listed-biological-products-companies-2016-2020---biotechnological-advances--favorable-policies-will-facilitate-fast-growth---research-and-markets-300456663.html
SOURCE Research and Markets